JERUSALEM, July 12 (Xinhua) -- Israeli biopharmaceutical company UroGen Pharma announced Thursday it has requested the U.S. Food and Drug Administration (FDA) to approve a new experimental medicine for bladder cancer.
The drug, named "UGN-102," is in the form of a mitomycin gel to be splashed into the bladder in a non-invasive treatment, the company said.
If approved, the company plans to begin phase-II clinical trials in the U.S. in the current quarter.
The company, founded in 2004, is developing advanced non-surgical treatments in the field of urology, with a focus on uro-oncology.
UroGen Pharma, traded on Nasdaq Stock Market, is headquartered in the city of Ra'anana, in the center of Israel.